Capital International, Inc. Sage Therapeutics, Inc. Transaction History

Capital International, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $956,503 - $1.38 Million	-17,429 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$70.65 - $96.76 $47,264 - $64,732	-669 Reduced 3.7%	17,429 $1.31 Million
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $1.49 Million - $2.28 Million	-25,573 Reduced 58.56%	18,098 $1.57 Million
Q3 2020 Nov 13, 2020	BUY	$41.13 - $62.45 $925,178 - $1.4 Million	22,494 Added 106.22%	43,671 $2.67 Million
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $6.81 Million - $11.3 Million	-262,609 Reduced 92.54%	21,177 $881,000
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $393,635 - $1.16 Million	15,053 Added 5.6%	283,786 $8.15 Million
Q4 2019 Feb 18, 2020	BUY	$60.18 - $154.77 $147,621 - $379,650	2,453 Added 0.92%	268,733 $19.4 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $35 Million - $47.4 Million	249,273 Added 1465.71%	266,280 $37.4 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $2.68 Million - $3.11 Million	17,007 New	17,007 $3.11 Million

216

47.8M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $353M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

Stay updated on Capital International, Inc. with notifications on news.